Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Corporate Update (November 2022)
6 slides from Getinge Ab Class B's corporate update, Nov 21, 2022
Slide 1: U.S. FDA includes Datascope in the Consent Decree
U.S. FDA includes Datascope in the Consent Decree Mattias Perjos, CEO November 21, 2022
Slide 2: Background to today’s news
Background to today’s news U.S. FDA includes Datascope in the Consent Decree • Datascope is a subsidiary of Getinge, and manufacturer of life-supporting medical devices such as Intra-Aortic Balloon Pumps which are sold globally • Datascope received a warning letter in 2019 related to findings relate
Slide 3: Consequences from today’s news
Consequences from today’s news U.S. FDA includes Datascope in the Consent Decree • Datascope is enforcing the ongoing actions to address the findings • Implementing a new operational quality organization with new leadership integrated in the business operations • Plan for further improvements will b
Slide 4: Q&A
Q&A US FDA includes Datascope in the Consent Decree I Getinge Presentation 21 November 2022 Page 4
Slide 5: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 6: Getinge - Passion for Life
“= Se A GETINGE PASSION FOR LIFE
Getinge — Corporate Update (November 2022) on 6ix